NCT03571620View on ClinicalTrials.gov

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

258

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

April 21, 2020

Conditions

Atopic Dermatitis

Interventions

DRUG

Q301 Cream

1.0% or 1.4% Q301 Cream

DRUG

Vehicle

Vehicle Control

Trial Locations (1)

27104

Wake Forest School of Medicine Department of Dermatology, Winston-Salem

All Listed Sponsors

lead

Qurient Co., Ltd.

INDUSTRY

NCT03571620 - Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter